Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Digestive Diseases and Sciences

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9125646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level

  1995cited by this paper
• Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C

  1995cited by this paper
• Serum levels of soluble interleukin-2 receptors and effects of interferon-α for patients with chronic hepatitis C virus

  1995cited by this paper
• Serum levels of interferon-alpha and -gamma in acute and chronic hepatitis B virus infection.

  1995cited by this paper
• Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.

  1994cited by this paper
• A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.

  1994cited by this paper
• Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

  1994cited by this paper
• Hepatic expression of interferon-α in chronic hepatitis B virus infection

  1994cited by this paper
• Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C.

  1994cited by this paper
• A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

  1994cited by this paper
• Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha.

  1994cited by this paper
• Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?

  1993cited by this paper
• Mechanisms of Action of Interferons

  1989cited by this paper
• Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

  1989cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

  1989cited by this paper
• Absence of detectable serum interferon in acute and chronic viral hepatitis

  1986cited by this paper
• Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life

  1986cited by this paper
• Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

  1986cited by this paper
• Interferon production by peripheral lymphocytes in HBsAg‐positive liver diseases

  1982cited by this paper
• Evaluation of the human interferon system in viral disease.

  1981cited by this paper
• Pharmacokinetic studies of interferons.

  1981cited by this paper

• Model of the adaptive immune response system against HCV infection reveals potential immunomodulatory agents for combination therapy

  2018cites this paper
• IL28B polymorphism, blood interferon-alpha concentration, and disease stage of HCV mono-infected and HCV-HIV co-infected patients.

  2013cites this paper
• Negative Regulation of Human Astrocytes by Interferon (IFN) α in Relation to Growth Inhibition and Impaired Glucose Utilization

  2012cites this paper
• Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.

  2007cites this paper
• Interferon γ-Inducible Protein 10: A Predictive Marker of Successful Treatment Response in Hepatitis C Virus/HIV-Coinfected Patients

  2007influential citation
• IFN-α Induced Adenosine Production on the Endothelium: A Mechanism Mediated by CD73 (Ecto-5′-Nucleotidase) Up-Regulation1

  2004cites this paper
• Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.

  2004cites this paper
• Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients.

  2002cites this paper
• New developments in interferon therapy.

  2001cites this paper
• IFN-alpha Receptor mRNA Expression in a United States Sample with Predominantly Genotype 1a/I Chronic Hepatitis C Liver Biopsies Correlates with Response to IFN Therapy

  1999cites this paper
• Kinetics of serum soluble tumour necrosis factor receptor (TNF‐R) type‐I and type‐II after a single interferon‐alpha (IFN‐α) injection in chronic hepatitis C

  1999cites this paper
• Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta.

  1999cites this paper
• Enhancing the response to interferon-alpha.

  1999cites this paper
• Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

  1998cites this paper
• Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

  1998cites this paper
• Activation of the endogenous interferon system, expression of interferon-alpha receptors, and response to interferon therapy in chronic hepatitis C.

  1997cites this paper